Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated with its now-discontinued heartburn drug Zantac, according to people familiar with the deal.
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle ... which sold Zantac between 1998 and 2006, said it continues to “vigorously defend against Zantac lawsuits, which it ...
Pfizer Inc. has agreed to settle more than ... GSK has settled some Zantac cases before they could go to trial. News of the Pfizer settlement surfaced in a filing in state court in Delaware ...
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with ...
opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits ... added. Pfizer did not immediately reply to Reuters' request for comment. First approved in 1983, Zantac ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
London: Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.